New hope for lung cancer patients Who've run out of options?
NCT ID NCT07306624
First seen Jan 03, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase 2 trial tests a new drug called nelmastobart combined with the chemotherapy docetaxel in 62 people with advanced non-small cell lung cancer that no longer responds to platinum chemo or immunotherapy. The goal is to see if the combination can slow cancer growth and improve survival. Participants must have a specific marker (BTN1A1 TPS score ≥50) to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kangbuk Samsung Hospital
RECRUITINGSeoul, South Korea
Contact
-
Korea University Anam Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Bundang Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
The Catholic University of Korea St. Vincent's Hospital
NOT_YET_RECRUITINGGyeonggi-do, South Korea
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nelmastobart and docetaxel
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer who have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 62 participants, so results may not apply to everyone. The combination may cause side effects and might not improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.